Patents by Inventor Tommi Salmi

Tommi Salmi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER
    Publication number: 20240131030
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 25, 2024
    Inventors: Jason PAIK, Tommi Salmi, Ying Ou
  • Methods of treating B-cell proliferative disorder
    Patent number: 11911386
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: February 27, 2024
    Assignee: BeiGene Switzerland GmbH
    Inventors: Jason Paik, Tommi Salmi, Ying Ou, Motohisa Takai
  • Methods of treating B-cell proliferative disorder
    Patent number: 11896596
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: February 13, 2024
    Assignee: BeiGene Switzerland GmbH
    Inventors: Jason Paik, Tommi Salmi, Ying Ou, Motohisa Takai
  • METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER
    Publication number: 20230405013
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Application
    Filed: May 31, 2023
    Publication date: December 21, 2023
    Inventors: Jason PAIK, Tommi SALMI, Ying OU
  • METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER
    Publication number: 20230398122
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Application
    Filed: June 6, 2023
    Publication date: December 14, 2023
    Inventors: Jason PAIK, Tommi SALMI, Ying OU
  • Methods of treating B-cell proliferative disorder
    Patent number: 11786531
    Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: October 17, 2023
    Assignee: BeiGene Switzerland GmbH
    Inventors: Jason Paik, Tommi Salmi, Ying Ou